FDA Grants Breakthrough Therapy Designation to Olomorasib With Pembrolizumab for NSCLC

FDA Grants Breakthrough Therapy Designation to Olomorasib With Pembrolizumab for NSCLC

The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

FDA Grants Breakthrough Therapy to Olomorasib in Lung Cancer Subset

The FDA granted Breakthrough Therapy designation to olomorasib plus Keytruda for unresectable advanced or metastatic NSCLC with a KRAS G12C mutation.

FDA grants breakthrough therapy status to Eli Lilly's olomorasib

This designation applies when olomorasib is used in combination with the anti-PD-1 therapy Keytruda (pembrolizumab) for the initial treatment of unresectable advanced or metastatic non-small cell lung cancer The post FDA grants breakthrough therapy status to Eli Lilly’s olomorasib appeared first on Pharmaceutical Business review.

Lilly's Olomorasib Receives US FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed Metastatic KRAS G12C-Mutant Lung Cancers

Eli Lilly and Company announced that the US FDA has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1 therapy KEYTRUDA for the first-line treatment of patients with unresectable advanced or metastatic NSCLC with a KRAS G12C mutation and PD-L1 expression ≥ 50%. [Eli Lilly and Company] Press Release